‘I’ve worked in this field for more than 10 years and have not seen anything like this.’
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.
The study is the first to demonstrate an intravenous medication that can cross the blood-brain barrier.
The discovery could one day enable new clinical therapies for treating glioblastoma, the most common and aggressive form of brain cancer in adults, and one whose incidence is rising in many countries. Today’s median survival for patients with glioblastoma is around 18 months; the average 5-year survival rate is below 5%.
In combination with radiation, the U-M team’s intravenously injected therapy led to long-term survival in seven out of eight mice. When those seven mice experienced a recurrence of glioblastoma, their immune responses kicked in to prevent the cancer’s regrowth—without any additional therapeutic drugs or other clinical treatments.
“It’s still a bit of a miracle to us,” said Joerg Lahann, the Wolfgang Pauli Collegiate Professor of Chemical Engineering and a co-senior author of the study. “Where we would expect to see some levels of tumor growth, they just didn’t form when we rechallenged the mice. I’ve worked in this field for more than 10 years and have not seen anything like this.”
The findings suggest that the U-M team’s combination of therapeutic drugs and nanoparticle delivery methods not only eradicated the primary tumor, but resulted in immunological memory, or the ability to more quickly recognize—and attack—remaining malignant cancer cells.
“This is a huge step toward clinical implementation,” said Maria Castro, the R.C. Schneider Collegiate Professor of Neurosurgery and a co-senior author of the study. “This is the first study to demonstrate the ability to deliver therapeutic drugs systemically, or intravenously, that can also cross the blood-brain barrier to reach tumors.”
Five years ago, Castro knew how she wanted to target glioblastoma. She wanted to stop a signal that cancer cells send out, known as STAT3, to trick immune cells into granting them safe passage within the brain. If she could shut down that pathway with an inhibitor, the cancer cells would be exposed and the immune system could eliminate them. But she didn’t have a way to get past the blood-brain barrier.
She attended a workshop at the Biointerfaces Institute, which Lahann leads, and the two discussed the problem. Lahann’s team began working on a nanoparticle that could ferry a STAT3 inhibitor past the blood-brain barrier.
A protein called human serum albumin, which is present in blood, is one of the few molecules that can cross the blood-brain barrier, so Lahann’s team used it as the structural building block for their nanoparticles. They used synthetic molecules to link these proteins up and then attached the STAT3 inhibitor and a peptide called iRGD, which serves as a tumor homing device.
Over the course of three weeks, a cohort of mice received multiple doses of the new nanomedicine, extending their median survival to 41 days, up from 28 days for those untreated. Following that success, the team performed a second mouse study using the drug alongside today’s current standard of care: focused radiotherapy. Seven of the eight mice reached long-term survival and appeared completely tumor-free, with no signs of malignant, invasive tumor cells.
The researchers say their synthetic protein nanoparticles could be adopted, after further development and preclinical testing, to deliver other small-molecule drugs and therapies to currently “undruggable” solid-based tumors.
The study, “Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy,” appears in Nature Communications.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Mum-of-three, 25, is widowed after love of her life dies from canceron January 23, 2021 at 6:01 pm
To anyone who knew them, Victorian couple Chloe and Peter Cook were the picture of 'happily ever after'. Their world was shattered when Peter lost his battle just 32 days after being diagnosed.
- Another new treatment for Glioblastomaon January 22, 2021 at 12:35 pm
Dr Ross Walker talks about another new trial into treating Glioblastoma, one of the most aggressive brain cancers.
- Recurrent Glioblastoma Brain Tumors With Fewer Mutations Respond Better to Immunotherapyon January 22, 2021 at 6:00 am
The treatment of glioblastoma brain tumors has remained a significant challenge, as some tumors respond to new immunotherapies after they've grown back, whereas others do not. Although the tumors ...
- Evgen Pharma CEO hails pre-clinical data from lead drug in glioma and glioblastoma modelson January 21, 2021 at 12:10 am
Work carried out in collaboration with an unnamed but prominent European university showed tumour shrinkage and significantly extended survival times ...
- Existing drugs may cut off 'fuel supply' to an aggressive brain canceron January 16, 2021 at 4:28 am
New research shows that a form of aggressive brain cancer responds to drugs that inhibit the activity of mitochondria, or the 'powerhouses' of cells.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Nanotech Jumps Blood-Brain Barrier To Kill Cancer in Miceon January 21, 2021 at 1:13 am
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research ...
- Nanobiotechnology-Based Strategies for Crossing the Blood–Brain Barrieron January 20, 2021 at 4:00 pm
Nanobiotechnology-Based Delivery of Therapeutics for Brain Tumors Across the BBB The application of anticancer drugs and gene therapy for malignant brain tumors may involve direct introduction ...
- Mimicking Nature's Nanocarrier: Synthetic Low-density Lipoprotein-like Nanoparticles for Cancer-drug Deliveryon January 20, 2021 at 4:00 pm
Tailored personalized therapy is fast emerging as the new paradigm in clinical nanomedicine ... as a potential targeted-delivery system for GBM. This is a well-suited application for nLDL ...
- NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021on January 15, 2021 at 5:59 pm
glioblastoma, and breast cancers. About NANOBIOTIX: www.nanobiotix.com Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly ...
- NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021on January 15, 2021 at 4:00 am
Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company”), a clinical-stage biotechnology company focuse ...